Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2025 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
August 28, 2025 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
August 20, 2025 09:48 ET | Source: Keros Therapeutics, Inc.

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
August 06, 2025 16:15 ET | Source: Keros Therapeutics, Inc.

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass.,...
August 06, 2025 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Reports Second Quarter 2025 Financial Results

LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
July 17, 2025 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
June 09, 2025 06:55 ET | Source: Keros Therapeutics, Inc.

Keros Announces Return of $375 Million in Excess Capital to Stockholders

LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
June 06, 2025 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
May 29, 2025 06:55 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros...
May 27, 2025 13:45 ET | Source: Keros Therapeutics, Inc.

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees

Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1’s Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value...